Date:9/30/2010

t"> var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ''; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key + ":" + first_result[key].toString() + "
"; if(key == "shortUrl") { shortURL = first_result[key].toString(); break; } } PostTwitter(); } function readCookie(name){ var cookieValue = ""; var search = name + "="; if(document.cookie.length > 0){ offset = document.cookie.indexOf(search); if (offset != -1){ offset += search.length; end = document.cookie.indexOf(";", offset); if (end == -1) end = document.cookie.length; cookieValue = unescape(document.cookie.substring(offset, end)) } } return cookieValue; } window.onload=function(){ OnNewsreleaseLoad(); var userid = readCookie('DMUserTrack'); var csid = 104064943; var newstogramURL = 'http://www.prnewswire.com/templates/PRN_MultiVu_URL_Reader?userid='+userid+'&csid='+csid; //var newstogramURL ='http://www.prnewswire.com/templates/prnwConfig.xml'; var delay = function() { sendToFlash('StartPlay',newstogramURL); }; setTimeout(delay,100,"JavaScript"); //setTimeout("sendToFlash('StartPlay', 'http://www.prnewswire.com/templates/prnwConfig.xml')",100); }; function ShortenURL() { //Bit.ly function call to shorten url BitlyClient.call('shorten', {'longUrl': formatURL()}, 'BitlyCB.alertResponse'); }

SOURCE Cordis Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema